Please use this identifier to cite or link to this item:
https://doi.org/10.3390/cancers13061316
DC Field | Value | |
---|---|---|
dc.title | Shifting the gears of metabolic plasticity to drive cell state transitions in cancer | |
dc.contributor.author | Wu, Zhengwei | |
dc.contributor.author | Lee, Yi Fei | |
dc.contributor.author | Yeo, Xun Hui | |
dc.contributor.author | Loo, Ser Yue | |
dc.contributor.author | Tam, Wai Leong | |
dc.date.accessioned | 2022-10-11T08:01:32Z | |
dc.date.available | 2022-10-11T08:01:32Z | |
dc.date.issued | 2021-03-15 | |
dc.identifier.citation | Wu, Zhengwei, Lee, Yi Fei, Yeo, Xun Hui, Loo, Ser Yue, Tam, Wai Leong (2021-03-15). Shifting the gears of metabolic plasticity to drive cell state transitions in cancer. Cancers 13 (6) : 1-22. ScholarBank@NUS Repository. https://doi.org/10.3390/cancers13061316 | |
dc.identifier.issn | 2072-6694 | |
dc.identifier.uri | https://scholarbank.nus.edu.sg/handle/10635/232122 | |
dc.description.abstract | Cancer metabolism is a hallmark of cancer. Metabolic plasticity defines the ability of cancer cells to reprogram a plethora of metabolic pathways to meet unique energetic needs during the various steps of disease progression. Cell state transitions are phenotypic adaptations which confer distinct advantages that help cancer cells overcome progression hurdles, that include tumor initiation, expansive growth, resistance to therapy, metastasis, colonization, and relapse. It is in-creasingly appreciated that cancer cells need to appropriately reprogram their cellular metabolism in a timely manner to support the changes associated with new phenotypic cell states. We discuss metabolic alterations that may be adopted by cancer cells in relation to the maintenance of cancer stemness, activation of the epithelial–mesenchymal transition program for facilitating metastasis, and the acquisition of drug resistance. While such metabolic plasticity is harnessed by cancer cells for survival, their dependence and addiction towards certain metabolic pathways also present therapeutic opportunities that may be exploited. © 2021 by the authors. Licensee MDPI, Basel, Switzerland. | |
dc.publisher | MDPI AG | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.source | Scopus OA2021 | |
dc.subject | Cancer stem cells | |
dc.subject | Cell state transition | |
dc.subject | Cellular plasticity | |
dc.subject | Epithelial–mesenchymal transition | |
dc.subject | Phenotype switching | |
dc.subject | Therapy resistance | |
dc.type | Review | |
dc.contributor.department | BIOCHEMISTRY | |
dc.description.doi | 10.3390/cancers13061316 | |
dc.description.sourcetitle | Cancers | |
dc.description.volume | 13 | |
dc.description.issue | 6 | |
dc.description.page | 1-22 | |
Appears in Collections: | Staff Publications Elements |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_3390_cancers13061316.pdf | 956.98 kB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License